Embla Medical Hf · OMXCOP:EMBLA
Embla Medical Hf — Q2 2025 Earnings Presentation
13 slides from Embla Medical Hf's earnings presentation, Jul 22, 2025
Slide 1: Q2 2025 Conference Call
A leading global provider of innovative mobility solutions Q2 2025 Conference Call Sveinn Sölvason, President and CEO G. Arna Sveinsdottir, CFO July 22, 2025 0
Slide 2: Key Highlights for Q2 2025
Key Highlights for Q2 2025 Q2 Performance & Guidance Strategic initiatives External USD sales growth Organic sales growth Streifeneder ortho.production Forbes’ Accessibility A black and white sign with red border AI-generated content may be incorrect. ✓ Agreement to invest in a majority +7% +5% ▪ Em
Slide 3: Streifeneder ortho.production will enable Embla Medical to reach more patients
Streifeneder ortho.production will enable Embla Medical to reach more patients as a full-range provider to a larger part of the global O&P market Fior Strategic rationale for Embla Medical An international developer and supplier of prosthetic and orthotics as ▪ Sound strategic rationale in line with
Slide 4: Growth across all regions in Q2 2025
Growth across all regions in Q2 2025 with stronger sales growth in EMEA driven by continued momentum in Prosthetics & Neuro Orthotics APAC APAC Q2: +3% Americas Q2: +3% 20 110 13% 7% 18 9% USDm 100 3% 16 6% USDm 2% 1% 3% 3% 90 -1% 14 80 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Sal
Slide 5: Prosthetics & Neuro Orthotics sales
Prosthetics & Neuro Orthotics sales % of total sales in Q2 Year-to-date sales Year-to-date growth Highlights ▪ EMEA: Continued strong performance in EMEA across key markets driven by volume growth and 50% good uptake from our recently launched innovation 237 9% such as Navii (Bionic knee) and Pro-Fl
Slide 6: Bracing & Supports sales
Bracing & Supports sales % of total sales in Q2 Year-to-date sales Year-to-date growth Highlights ▪ EMEA: Good performance in selected regions but overall performance was soft. 73 -1% ▪ Americas: Sales in B&S continued to be soft, partly USD million organic growth ascribed to lower patient volumes f
Slide 7: Patient Care sales
Patient Care sales % of total sales in Q2 Year-to-date sales Year-to-date growth Highlights ▪ EMEA: Good performance in several European markets but partly offset by softer sales in selected 34% markets, partly impacted by Easter holidays shifting 144 0% between current and comparable quarters. USD
Slide 8: EBITDA margin expanding by 1%-points in 1H'25 to 20%
EBITDA margin expanding by 1%-points in 1H’25 to 20% (vs 19% in 1H 2024) Expansion driven by higher Gross Profit margin and cost discipline in SG&A Gross Profit and Gross Profit margin Highlights USD million ▪ Gross Profit: Gross profit margin (before special items) in 1H’25 was 63% compared to 62%
Slide 9: Cash flow and leverage
Cash flow and leverage Capital expenditures and % of sales Free cash flow and % of sales Net Interest-Bearing Debt and Leverage USD million on actual rate USD million on actual rate USD million on actual rate 11 470 460 472 10 34 437 33 414 9 8 3.1x 6 2.8x 2.6x 2.6x 18 15% 2.5x 15% 2.4x 2.3x 12 2.0x
Slide 10: 2025 Guidance
2025 Guidance Guidance as of Guidance as of 1H 2025 July 22 2025 April 29 2025 Sales growth 5-6% 4% 5-8% Organic EBITDA margin Before special 20-21% 20% 20-21% items For modeling purposes: Special items None None None In USD million CAPEX 3-4% 4% 3-4% % of sales Tax 23-24% 24% 23-24% Effective tax r
Slide 11: Q&A: Key messages from Q2 2025
Q&A Key messages from Q2 2025 1. Well on track with our strategic initiatives: ✓ Agreement to invest 51% in Streifeneder ortho.production ✓ Fior & Gentz awarded new reimbursement code in the US ✓ Halfway through with our ForMotion rebranding 2. Continued strong performance in Prosthetics and Neuro O
Slide 12: Contact our Investor Relations
Contact our Investor Relations Financial calendar and events July 22, 2025 Interim report Q2 2025 July 22, 2025 Q2 2025 HCA Capital virtual presentation and Q&A July 22, 2025 Q2 2025 US Virtual Road Show (SEB) Aug 19, 2025 Q2 2025 Road Show Copenhagen (SEB) Investor Relations Aug 20, 2025 Nordea Sma
Slide 13: Forward-looking statement
Forward-looking statement This presentation contains forward-looking statements, which reflect the Management’s current views with respect to certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there is no assura